Thursday, February 13, 2025
HomeFunding Red Queen Therapeutics Raises $55 Million Series A Funding

[Funding News] Red Queen Therapeutics Raises $55 Million Series A Funding

Existing and emerging viral threats endanger all of us, but people with impaired immune systems are at substantially greater risk. Apple Tree Partners (ATP), a leader in life sciences venture capital, unveiled Red Queen Therapeutics, a clinical-stage biotechnology company developing novel antiviral treatments for the general population and especially for immunocompromised patients who are at increased risk of serious illness or death from common and emerging viral pathogens.

Existing and emerging viral threats endanger all of us, but people with impaired immune systems are at substantially greater risk. Apple Tree Partners (ATP), a leader in life sciences venture capital, unveiled Red Queen Therapeutics, a clinical-stage biotechnology company developing novel antiviral treatments for the general population and especially for immunocompromised patients who are at increased risk of serious illness or death from common and emerging viral pathogens.

Read also – [Funding News] Seeq Raises $50 Million Series D Funding

Red Queen Therapeutics is co-founded by ATP and Loren Walensky, M.D., Ph.D., Professor of Pediatrics at Harvard Medical School, Principal Investigator and Attending Physician in the Department of Pediatric Oncology at the Dana-Farber Cancer Institute/Boston Children’s Hospital, and Director of the Harvard/MIT M.D.-Ph.D. Program. Red Queen is operating with a $55 million Series A commitment from ATP.

Read also – [Funding News] Artax Biopharma Raises $8 Million Convertible Debt Funding

The company also has additional funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, specifically for preclinical development of a pan-influenza therapeutic.

“As existing viruses circulate and spread and new viruses arise, treating sick individuals and curtailing transmission in vulnerable communities is an ever-present urgent medical need and public health imperative,” said Seth Harrison, M.D., Founder and Managing Partner of Apple Tree Partners and Chair of the Board of Directors of Red Queen Therapeutics. “With ATP support, Red Queen has successfully brought its novel technology for rapidly designing and developing new antivirals through clinical proof of concept, and we anticipate continued strong progress of the company’s programs in multiple viral diseases.”

“Red Queen’s stapled lipopeptides act on the core fusion machinery of the virus, which is highly conserved across variants. This mechanism enables sustained activity against emerging variants and makes Red Queen therapies well-suited not only for individualized care in high-risk patients but also stockpiling and rapid deployment for population-level interventions,” said Mark Mitchnick, M.D., Chief Executive Officer of Red Queen Therapeutics and a Venture Partner at ATP. “Our platform technology has demonstrated its potential for activity across many families of viruses, and we have refined our capabilities to a point where we can customize lipopeptides in weeks. We are excited by both the broad and ready utility of the platform and the therapeutic promise of the product candidates it produces. We just completed a very promising Phase 1 trial of our SARS-CoV-2 therapeutic and are in discussions around the Phase 2, and we have a robust pipeline.”

About Red Queen Therapeutics

Red Queen Therapeutics, a clinical-stage biotechnology company co-founded by Apple Tree Partners (ATP) and biomedical researcher Loren Walensky, M.D., Ph.D., is applying its proprietary stapled lipopeptide technology to develop and deliver new treatments for a broad range of viruses, including coronaviruses, influenzas, and other enveloped viruses. The Red Queen platform mechanism of action, fusion inhibition, is a mode of early intervention that can prevent or mitigate viral infection, enabling accelerated viral clearance and avoidance of severe disease. Because Red Queen therapies target the highly conserved mechanism of viral fusion, they can be used across entire viral families and their variants.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular